GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » Institutional Ownership

Core One Labs (XCNQ:COOL) Institutional Ownership : 0.18% (As of Apr. 29, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Core One Labs Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Core One Labs's institutional ownership is 0.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Core One Labs's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Core One Labs's Float Percentage Of Total Shares Outstanding is 0.00%.


Core One Labs Institutional Ownership Historical Data

The historical data trend for Core One Labs's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Institutional Ownership Chart

Core One Labs Historical Data

The historical data trend for Core One Labs can be seen below:

2021-07-31 2021-08-31 2021-09-30 2021-10-31 2021-11-30 2021-12-31 2022-01-31 2022-12-31 2023-01-31 2023-02-28
Institutional Ownership 2.46 2.53 2.33 2.33 2.33 0.97 0.86 0.20 0.18 0.18

Core One Labs Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Core One Labs (XCNQ:COOL) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.